What is the appropriate work‑up for a patient who develops nausea, vomiting, and dizziness after taking Wegovy (semaglutide)?

Work-Up for Nausea, Vomiting, and Dizziness After Taking Wegovy

These symptoms are expected, common adverse effects of Wegovy (semaglutide) that occur in 17-44% of patients for nausea, 7-25% for vomiting, and are typically self-limited with GLP-1 receptor agonists. 1, 2 The work-up should focus on ruling out serious complications while recognizing that most cases represent transient gastrointestinal intolerance.

Initial Assessment Priority

First, determine if the patient has severe symptoms requiring immediate intervention:

• Severe dehydration (poor skin turgor, orthostatic hypotension, decreased urine output)
• Signs of acute pancreatitis (severe epigastric pain radiating to back, elevated lipase >3x upper limit)
• Symptoms of acute gallbladder disease (right upper quadrant pain, fever, Murphy's sign)
• Inability to maintain oral intake for >24 hours
• Signs of bowel obstruction (absent bowel sounds, severe distention, obstipation)

1, 2

Diagnostic Work-Up Algorithm

Step 1: Laboratory Evaluation

Order the following labs immediately:

• Serum lipase - to exclude pancreatitis (GLP-1 RAs carry increased risk) 1
• Comprehensive metabolic panel - assess for:
  • Acute kidney injury (reported with volume depletion from GI symptoms) 2
  • Electrolyte abnormalities from vomiting
  • Renal function baseline (eGFR)
• Blood glucose - if patient has diabetes, assess for hypoglycemia (6.2% incidence with Wegovy in diabetics) 2

Step 2: Imaging Studies (If Indicated)

Obtain right upper quadrant ultrasound if:

• Right upper quadrant pain present
• Lipase elevation noted
• Symptoms persist beyond expected GI side effects

Rationale: Cholelithiasis occurs in 1.6% and cholecystitis in 0.6% of Wegovy-treated adults (higher rates in pediatrics: 3.8% and 0.8% respectively) 2

Consider CT abdomen/pelvis if:

• Severe abdominal pain with distention
• Concern for bowel obstruction (rare but reported with semaglutide) 3
• Symptoms not improving with conservative management

Step 3: Assess Volume Status and Renal Function

Monitor closely for acute kidney injury, particularly if:

• Patient reports severe nausea, vomiting, or diarrhea
• Pre-existing renal impairment
• Taking concomitant medications affecting renal function

2 The FDA label specifically warns that acute kidney injury requiring hemodialysis has been reported, primarily in patients with volume depletion from GI symptoms.

Management Based on Severity

Mild Symptoms (Nausea without vomiting, no dehydration)

• Continue Wegovy at current dose if tolerable
• Implement dietary modifications: smaller portions, avoid high-fat foods
• Consider antiemetics: ondansetron 8mg as first-line 4
• Reassure patient these symptoms typically resolve with continued use 5, 6

Moderate Symptoms (Persistent vomiting, mild dehydration)

• Hold Wegovy temporarily
• Provide IV hydration and electrolyte replacement 4
• Antiemetic therapy: ondansetron, with prochlorperazine or metoclopramide as second/third-line 4
• Restart at lower dose when symptoms resolve (requires restarting at 0.25mg weekly) 1

Severe Symptoms (Inability to maintain oral intake, severe dehydration, organ dysfunction)

• Discontinue Wegovy
• Hospitalize for IV hydration and monitoring
• Complete work-up for pancreatitis and gallbladder disease
• Monitor renal function closely 2

Critical Pitfalls to Avoid

Do not assume all GI symptoms are benign drug effects. While nausea/vomiting are common with GLP-1 RAs, the FDA label specifically warns about:

• Acute pancreatitis (discontinue if suspected, do not restart if confirmed) 7, 2
• Acute gallbladder disease (increased risk even accounting for weight loss) 2
• Acute kidney injury from volume depletion 2

Do not overlook gastroparesis risk. Wegovy delays gastric emptying and should not be used in patients with severe gastroparesis 1, 2. If symptoms are severe or persistent, consider gastric emptying study.

Monitor for diabetic retinopathy progression if patient has diabetes and history of retinopathy (4% incidence vs 2.7% placebo) 2

Special Considerations

If patient is on insulin or sulfonylureas: Check blood glucose immediately - hypoglycemia risk is significantly increased (6.2% vs 2.5% placebo) 2

Dizziness specifically: May represent:

• Orthostatic hypotension from volume depletion (check orthostatic vital signs)
• Hypoglycemia if diabetic
• Increased heart rate (mean increase 1-4 bpm, but 26% have increases ≥20 bpm) 2

The key distinction: Gradual dose titration should have prevented severe symptoms 1. If symptoms occur despite proper titration, this suggests either inadequate titration schedule or patient intolerance requiring dose reduction or discontinuation.